Delivery Order SPE2DB25D3108-SPE2DB25FPECA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $22,782.76 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 ml pen injections on April 24, 2025, with completion scheduled for April 25, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a $1,143.89 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. The contract, which represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), is scheduled for completion by August 18, 2025. This delivery order was competitively awarded without...
- The Defense Logistics Agency awarded a $14,404.96 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Zepbound (semaglutide) 15 mg/0.5 mL pen injectors with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $19,682.68 delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 18, 2025. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a $1,525.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen (semaglutide) on September 2, 2025, with a completion date of September 3, 2025. This non-competitive, non-set-aside delivery order will be fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $7,848.75 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 21, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single transaction under the company's larger pharmaceutical supply framework with the federal...
- The Defense Logistics Agency awarded a $35,358.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections. The contract, designated as a non-set-aside competitive award, calls for completion by August 18, 2025, with performance at the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections, with a ceiling value of $1,143.87 and an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery...
- The Defense Logistics Agency awarded a $13,120.39 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,030.39 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This is a firm fixed price, competitively awarded contract with a completion date of September 29, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation, indicating it was awarded through...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPECADelivery Order
The Defense Logistics Agency awarded a $8,851.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections on September 26, 2025, with completion by September 29, 2025. The contract was competitively awarded with no set-aside designation and is based in Conshohocken, Pennsylvania. This delivery order represents a pediatric formulation of the diabetes and weight management medication and falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal vendor for military and veteran healthcare systems through DLA's Medical Supply Chain. As a child contract under the broader IDC, this delivery order leverages AmerisourceBergen's established capability to supply brand-name and generic pharmaceuticals, specialty medications, and medical supplies to support Defense Health Agency operations and other federal healthcare customers globally. The company's extensive federal contract portfolio demonstrates consistent competitively-awarded success across multiple therapeutic domains and transaction sizes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 9/26/25 |